• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Awakn Life Sciences Corp (OP: AWKNF )

    0.0888 +0.0088 (+11.00%)
    Streaming Delayed Price Updated: 2:32 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Awakn Life Sciences Corp

    < Previous 1 2 3 4 5 Next >
    Awakn Partners With University Of Nottingham For Preclinical Testing Of Psychoactive Therapy
    Awakn Life Sciences partners with the University of Nottingham to advance in vivo testing of its aminoindane therapy for PTSD, with results expected by late 2024. 
    Via Benzinga
    Investors Back Awakn's Psychedelic Therapies, As Company Doubles Private Placement To $2M
    Awakn Life Sciences expands its private placement to $2 million, closing the fourth tranche with $394,286 raised to accelerate research into addiction treatments. 
    Via Benzinga
    Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
    Via Benzinga
    Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
    Via Benzinga
    Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More
    Discover the latest research on psychedelics, from anti-inflammatory effects to end-of-life therapy. New journal issue and online course available. 
    Via Benzinga
    Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More
    President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also... 
    Via Benzinga
    Awakn Life Sciences Enters Into Global Licensing Agreement For Sublingual Delivery Formulation
    Awakn Life Sciences (OTC: AWKNF), a clinical-stage biotechnology company specializing in the development of ketamine-assisted treatments for addiction, has enter 
    Via Benzinga
    Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More
    GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan 
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center
    The U.K. Medicines and Healthcare Regulatory Agency (MHRA) has green-lighted two separate Phase 3 trials conducted by Compass Pathways (NASDAQ: CMPS) for Treatment-Resistant Depression and Awakn Life... 
    Via Benzinga
    U.K.'s Prof. David Nutt Ranked World's Top Psychopharmacologist: More On His Contributions & Advocacy
    Professor David Nutt, a cognitive sciences, addiction, cannabis and psychedelics researcher, has been ranked the #1 psychopharmacologist by ScholarGPS, a California-based American company owned and... 
    Via Benzinga
    Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
    Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification 
    Via Benzinga
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Awakn Life Sciences Submits CTA For Phase III Alcohol Use Disorder Clinical Trial
    Awakn Life Sciences Corp. (OTC: AWKNF), a biotech firm focused on developing therapies for addiction, with a primary emphasis on Alcohol Use Disorder (AUD), has taken a big step toward Phase III... 
    Via Benzinga
    Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
    First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published 
    Via Benzinga
    Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
    A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances... 
    Via Benzinga
    Awakn Life Sciences Becomes Pure R&D Biotech After Sale Of Norway Clinics
    As part of its business restructuring process and following its London clinics busin 
    Via Benzinga
    Awakn Life Sciences On Track With Phase 3 Trial To Research Substance Use Disorder
    On this new Psychedelics Exclusive podcast, TDR Founder Shadd Dales interviews Awakn Life Sciences Corp. (OTC: AWKNF) CEO Anthony Tennyson, as his company moves closer towards a Phase III clinical... 
    Via Benzinga
    Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More
    First Country Allowing MDMA & Psilocybin For Depression, PTSD Makes Headlines On Saturday, July 1, 2023, Australia became the first country to allow physicians to prescribe MDMA to treat post-traumatic... 
    Via Benzinga
    Awakn Life Sciences Sells London Clinics Business, Hopes To Divest Norwegian Unit Next
    Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) sold its London subsidiary and healthcare clinic. 
    Via Benzinga
    Awakn Life Sciences Announces Closing Of Second Tranche And Upsizing Of Previous Private Placement
    UK-based psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) announced the closing of the second tranche of its latest non-brokered private placement as well as an upsizing of the original... 
    Via Benzinga
    Awakn To Focus On R&D Of Addiction Therapies, Moves Away From Ketamine Treatment For Alcoholism
    Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) is set to exit ketamine healthcare services to focus solely on research and development of therapeutics to treat addiction and licensing of... 
    Via Benzinga
    Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
    Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued 
    Via Benzinga
    Awakn's Q4 2023 And Annual Financials, +500% YoY Revenue Increase Following Network Expansion
    The UK-based psychedelics biotech company Awakn Life Sciences Corp. (OTCQB: AWKNF) reported on its financial results and business highlights for the three and twelve months ended Jan. 31, 2023.   
    Via Benzinga
    Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
    LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a... 
    Via Benzinga
    Severe Alcohol Use Disorder Patients Will Try Ketamine Therapy At Awakn's New Phase 3 Study
    The research partnership between UK-based psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) and the University of Exeter for an upcoming 
    Via Benzinga
    EXCLUSIVE: MDMA Therapy Experts Debate Upcoming Approval And Psychedelic Market Opps
    In the current psychedelics landscape, one of the most important topics is compound legality.  While it's possible that MDMA-assisted therapy will eventually be federally approved in the U.S., what... 
    Via Benzinga
    Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More
    Revolutionizing Psychedelics: 2 Industry Leaders Team Up On Clinical-Grade MDMA Capsules 
    Via Benzinga
    Awakn's Psychedelics Medical Chief Steps Down, Shifts In Company's Stocks And Ownership
    Awakn Life Sciences Corp. (OTCQB: AWKNF), the biotech company developing psychedelic therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD) shared its recent corporate... 
    Via Benzinga
    EXCLUSIVE: Ketamine Therapy Provider Nushama Co-Founder On Shifting From A Consciousness Of Blame Into A Space Of Responsibility
    In light of the latest news regarding the DEA’s telehealth regulations and the 
    Via Benzinga
    Major Psychedelics VC & EFT Directors Will Share Valuable Insights At Upcoming Benzinga Event
    The Benzinga Psychedelics Capital Conference (PCC) is rapidly becoming the place to be for all those interested or involved in the space. In addition to being the place where deals are done, you'll... 
    Via Benzinga
    Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
    Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been... 
    Via Benzinga
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.